KospicyKorean filings in English
Filings / HLB Pharmaceutical

Beneficial Ownership Report (5%) — Standard Form

HLB Pharmaceutical · 주식등의대량보유상황보고서(일반)

SC 13D/GKOSDAQ · 047920 Filed 2026-11-16Korean original on DART

English form view 74% translated

Translated from a fixed dictionaryLeft in Korean (free text, names)Numbers and dates are copied unchanged

Report on large shareholdings (general)

6.1

에이치엘비제약(주)

0000

Report on Large Holdings of Shares, etc.

(General form: reports under Article 147 of the Financial Investment Services and Capital Markets Act with the purpose of influencing management control)
To: Financial Services CommissionReporting obligation date:2026-11-09
To: Korea ExchangeReport reference date:2026-11-16
Reporting person:에이치엘비생명과학(주)
Summary
Issuer name에이치엘비제약(주)Relationship to IssuerLargest Shareholder
Report TypeChange
Number of Shares Held and Holding RatioNumber of Shares HeldHolding Ratio
Previous Report8,331,40818.97
Current Report8,331,40818.97
Shares under key agreements: number and ratioNumber of shares, etc.Ratio
Previous Report3,785,1888.63
Current Report4,346,1579.90
Number of voting rights and holding ratioNumber of Voting RightsHolding Ratio
Previous Report--
Current Report--
Voting rights under key agreements: number and ratioNumber of Voting RightsRatio
Previous Report--
Current Report--
Reason for Report주식담보대출 일부 상환 및 신규계약 체결
※ The reporting person confirms that holdings of shares, etc. by the reporting person and specially related parties as of the reference date are accurately stated per applicable laws and filing instructions, with no material misstatement or omission.

Part 1 Report Overview

1. Issuer information

Company Name에이치엘비제약(주)Company code047920
Entity typeKOSDAQ-Listed CompanyTotal Issued Voting Shares (shares)43,561,688

2. Major shareholder information

a. Reporting person

(1) Reporting person overview

Report TypeChangeJoint signatories
Reporting person typeDomestic corporationNationalityRepublic of Korea
Basis for Reporter Classification (only if reported as a statutory partnership or other entity)-
Name (Entity Name)Korean에이치엘비생명과학(주)Chinese characters (English)HLB Life Science Co., Ltd.
Address (Head Office) [Town/District Level Only]경기도 화성시 영천동Date of Birth or Business Registration No., etc.116-81-69278
Occupation (business)의료용 물질 및 의약품 제조업 외Relationship to IssuerLargest Shareholder
Business contact and person in chargeAffiliated company에이치엘비생명과학(주)DepartmentCorporate Planning Team
Position이사대우Phone Number02-262**
Name이기언Fax number02-262**
Email address**[email protected]

(2) Reporting Person Details (for Corporations, Other Organizations, Statutory Associations, or Civil-Law Partnerships)

Legal formCo., Ltd.
Total Assets (or Total Assets Under Management)478,093,566,716Total Liabilities180,351,365,141
Total Equity297,742,201,575Paid-in Capital61,432,097,000
Representative (representative or managing partner)백윤기
Decision-Making Body (Decision Maker)이사회, 주주총회
Largest Shareholder (Largest Investor)에이치엘비(주)Largest Shareholder Ownership (%) (Largest Investor Contribution Ratio)16.98
(*) 상기 자산총액, 부채총액, 자본총액 및 자본금은 직전년도(2025년도)말 연결재무제표 기준입니다.

【보고자의 최대주주가 법인, 기타단체, 법령상조합, 민법상 조합의 경우】

Legal formCo., Ltd.
Total Assets (or Total Assets Under Management)930,177,639,023Total Liabilities435,763,869,963
Total Equity494,413,769,060Paid-in Capital66,370,831,500
Representative (representative or managing partner)김홍철
Decision-Making Body (Decision Maker)이사회, 주주총회
Largest Shareholder (Largest Investor)진양곤Largest Shareholder Ownership (%) (Largest Investor Contribution Ratio)7.13
(*) 상기 자산총액, 부채총액, 자본총액 및 자본금은 직전년도(2025년도)말 연결재무제표 기준입니다.

b. Specially related parties

(1) Specially related party overview

No.NameCategorySpecific Relationship to ReporterDate of Birth or Business Registration No., etc.NationalityAddress (Location)Occupation (Business)Relationship to Issuer
1진양곤Individual (Domestic)Executive660114Republic of Korea경기도 성남시 정자동ExecutiveExecutive officers (registered)
2박재형Individual (Domestic)Officer of Affiliate660926Republic of Korea서울시 강남구 도곡동에이치엘비제약(주) 대표이사Executive officers (registered)
3김만규Individual (Domestic)Officer of Affiliate750705Republic of Korea서울시 성동구 응봉동에이치엘비제약(주) 상무이사Executive officers (registered)
4진유림Individual (Domestic)Other941017Republic of Korea경기도 성남시 정자동-Shareholder
5진인혜Individual (Domestic)Other961028Republic of Korea경기도 성남시 정자동-Shareholder
* Address to town/district level only

(2) Details of specially related parties (for corporations, other entities, statutory or civil-law partnerships)

Legal form-
Total Assets (or Total Assets Under Management)-Total Liabilities-
Total Equity-Paid-in Capital-
Representative (representative or managing partner)-
Decision-Making Body (Decision Maker)-
Largest Shareholder (Largest Investor)-Largest Shareholder Ownership (%) (Largest Investor Contribution Ratio)-

c. Collective investment manager

(Only if the reporting person or specially related party is a "collective investment vehicle" under Regulation Art. 3-10(2))

(1) Collective investment manager overview

No.NameBusiness Registration No., etc.Target collective investment vehicleNationalityAddress (Location)Remarks
-------

(2) Collective investment manager details

Legal form-
Paid-in Capital-Total Assets Under Management-
Representative-
Decision-Making Body (Decision Maker)-
Largest Shareholder (Corporate Representative)-Largest Shareholder Stake-

3. Shares, etc. held and holding ratio

Report reference dateReporting personShares, etc.Share CertificatesTotal Issued Voting Shares (shares)
Name of HolderNumber of Specially Related PersonsNumber of Shares, etc. (shares)Ratio (%)Number of Shares (shares)Ratio (%)
Previous Report2026-10-21에이치엘비생명과학(주)58,331,40818.977,981,40818.3243,561,688
This Report2026-11-16에이치엘비생명과학(주)58,331,40818.977,981,40818.3243,561,688
Change00.0000.000

4. Purpose of holding

Impact on management control
보고자는 에이치엘비제약(주)의 최대주주로서 자본시장과 금융투자업에 관한 법률 시행령 제154조 제1항 각 호에 대한 사항에 대하여 회사의 최대주주로서 회사에 영향력을 행사할 계획입니다.현재 아래 1~9 각호의 사항에 대한 세부계획은 없지만, 회사의 최대주주로서 회사의 업무집행과 관련한 각호의 사항이 발생할 경우에는 회사의 경영목적에 부합하도록 관련행위들을 결정할 예정입니다.- 자본시장과 금융투자업에 관한 법률 시행령 제154조 제1항 각 호(아래 1~9호) 1. 이사 및 감사의 선임ㆍ해임 또는 직무의 정지 2. 이사회 등 회사의 기관과 관련된 정관의 변경 3. 회사의 자본금의 변경 4. 회사의 합병, 분할 및 분할합병 5. 주식의 포괄적 교환 및 이전 6. 영업전부의 양수ㆍ양도 또는 금융위원회가 정하여 고시하는 중요한 일부의 양수ㆍ양도 7. 자산의 전부의 처분 또는 금융위원회가 정하여 고시하는 중요한 일부의 처분 8. 영업전부의 임대 또는 경영위임, 타인과 영업의 손익전부를 같이 하는 계약, 그 밖에 이에 준하는 계약의 체결ㆍ변경 또는 해약 9. 회사의 해산

5. Reason for change

Method of change-
Reason for change-
Reason for Change주식담보대출 일부상환 및 신규계약 체결

Part 2 Details of Large Holdings

1. Holdings by reporting person and specially related persons

A. Holdings by type of shares, etc.

RelationshipNameDate of Birth or Business Registration No., etc.Details of Shares Held
Share certificatesInstruments representing preemptive rightsConvertible bondsBonds with warrantsExchangeable bondsDepositary receiptsOtherTotal
Voting SharesShares Redeemable into Voting SharesShares Convertible into Voting SharesNumber of sharesRatio (%)
Reporting person에이치엘비생명과학(주)116-81-692786,167,695--------6,167,69514.05
Specially Related Party진양곤660114915,579--------915,5792.09
박재형660926657,378-------310,000967,3782.20
김만규750705--------40,00040,0000.09
진유림941017120,378--------120,3780.27
진인혜961028120,378--------120,3780.27
Aa1a2BCDEFG
H
Total Issued Voting Shares (I)Number of Potential Shares Held (a1+a2+B+C+D+E+F+G=H)Holding Ratio (%)
Holding Ratio of Shares, etc. [A+H / I+H-(E+F+G)※] × 100Share Holding Ratio (A / I) × 100
43,561,688350,00018.9718.32

※ Holding ratio calculated excluding from the denominator only exchangeable bonds exchangeable into shares, depositary receipts and derivative-linked securities with shares as underlying, and stock options settled in treasury shares

B. Holdings by form of holding

RelationshipName (Entity Name)Date of Birth or Business Registration No., etc.Type of holding equivalent to ownership (Article 142, Enforcement Decree of the Financial Investment Services and Capital Markets Act)Total
No. 1No. 2No. 3No. 4No. 5No. 6No. 7Number of sharesRatio
Reporting person에이치엘비생명과학(주)116-81-692786,167,695------6,167,69514.05
Specially Related Party진양곤660114915,579------915,5792.09
박재형660926657,378-----310,000967,3782.20
김만규750705------40,00040,0000.09
진유림941017120,378------120,3780.27
진인혜961028120,378------120,3780.27
※ Holdings equivalent to ownership (Article 142, Enforcement Decree of the Financial Investment Services and Capital Markets Act) - Item 1: owning shares, etc. for one's own account, in whatever name - Item 2: holding a right to claim delivery of shares, etc. under law, a sale, or other contract - Item 3: holding voting rights (including the right to direct voting) over the shares, etc. under law, a money trust, security, or other contract - Item 4: holding the authority to acquire or dispose of the shares, etc. under law, a money trust, security, discretionary investment, or other contract - Item 5: acquiring, through a unilateral reservation for sale of shares, etc., the right to complete the sale, and holding buyer status by exercising that right - Item 6: holding contractual rights under Article 5(1)(2) of the Act with shares, etc. as underlying assets, and holding buyer status by exercising those rights - Item 7: being granted stock options and holding buyer status by exercising them

2. Contracts on shares held

A. Contract status

Execution or amendment of key agreements (trust, collateral, lending, discretionary, OTC trading, joint holding, etc.)
Yes

*Voting rights on unreported holdings may be restricted if execution/amendment of material contracts is not reported

B. Contract details

No.Name (Entity Name)Relationship to ReporterDate of Birth or Business Registration No., etc.Type of shares, etc.Number of shares, etc.CounterpartyContract typeContract date (amendment date)Contract periodRatioRemarks
1박재형Related party660926Voting Shares38,521Korea Investment & Securities담보대출계약2026.08.312024.02.20~2026.11.300.09Stock-Backed Loan
2박재형Related party660926Voting Shares25,707Korea Investment & Securities담보대출계약2026.08.312025.06.02~2026.11.300.06Stock-Backed Loan
3박재형Related party660926Voting Shares117,206IBK투자증권담보대출계약2026.09.012026.09.01~2026.11.300.27Stock-Backed Loan
4박재형Related party660926Voting Shares109,506IBK투자증권담보대출계약2026.09.082026.09.08~2026.12.070.25Stock-Backed Loan
5박재형Related party660926Voting Shares66,010유안타증권담보대출계약2026.10.192026.10.19~2027.01.180.15Stock-Backed Loan
6에이치엘비생명과학(주)Self116-81-69278Voting Shares3,240,638Korea Investment & Securities담보대출계약2026.11.132026.06.30~2027.06.307.38Stock-Backed Loan
7에이치엘비생명과학(주)Self116-81-69278Voting Shares88,067IBK투자증권담보대출계약2026.11.092026.11.09~2027.02.150.20Stock-Backed Loan
8에이치엘비생명과학(주)Self116-81-69278Voting Shares660,502유화증권담보대출계약2026.11.092026.11.09~2027.05.071.50Stock-Backed Loan
Total (number of shares, etc.)4,346,157Total (ratio)9.90-

C. Additional details if the main contract is a security agreement

No.Number of shares, etc.Loan amountDebtorInterest rateCollateral maintenance ratioOther
138,521300,000,000박재형6.15200-
225,707200,000,000박재형6.15200-
3117,206500,000,000박재형6.00160-
4109,506500,000,000박재형6.00160-
566,010250,000,000박재형6.50200-
63,240,6386,500,000,000에이치엘비생명과학(주)6.00250-
788,067400,000,000에이치엘비생명과학(주)6.50160-
8660,5022,000,000,000에이치엘비생명과학(주)6.70200-

3. Holdings by proprietary and customer account (financial institutions only)

NameRelationship to ReporterBy accountTotal
Own Account (shares)Ratio (%)Customer account (shares)Ratio (%)Total (shares)Ratio (%)
--------
--------
Total------

Part 3 Material Changes Since Last Report Date

1. Summary of changes

a. Changes in shares, etc.

RelationshipNameDate of Birth or Business Registration No., etc.Details of Changes in Shares, etc.
Share certificatesInstruments representing preemptive rightsConvertible bondsBonds with warrantsExchangeable bondsDepositary receiptsOtherTotal
Voting SharesShares Redeemable into Voting SharesShares Convertible into Voting SharesNumber of sharesRatio (%)
Reporting person에이치엘비생명과학(주)116-81-69278-----------
Specially Related Party진양곤660114-----------
박재형660926-----------
김만규750705-----------
진유림941017-----------
진인혜961028-----------

2. Change details

a. Detailed changes in shares, etc.

(Unit: shares, KRW)
Name (Entity Name)Date of Birth or Business Registration No., etc.Change Date*Acquisition/disposal methodType of shares, etc.Change detailsAcquisition/disposal unit price**Remarks
Before ChangeChangeAfter Change
-----------

* For trades on the securities market, the contract date

** For securities other than shares, the exercise (conversion/exchange) price of the securities or the unit price of shares acquired/disposed of through exercise of rights; amounts in ( ) are the unit price of the securities

3. Source of acquisition funds

(1) Overview of acquisition funds

(Unit: KRW)
NameDate of birth or business registration no., etc.Own funds (H)Borrowings (I)Other (J)Total (H+I+J)
------

(2) Origin and source of acquisition funds

- N/A